News
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for its anti-tissue factor pathway inhibitor
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON Secures Upgraded Credit Rating from Moody’s Investors Service
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
Cosmo confirms full redemption in cash of €175m Convertible Bonds
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
EQS-News: Formycon announces participation in international Investor Conferences in Q1/2024
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc.
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board